Typhoid vaccination: The Asian experience

Expert Review of Vaccines

Volumn 7, Issue 5, 2008, Pages 547-560

  DeRoeck, Denise ^a   Ochiai, R Leon ^a   Yang, Jin ^b   Dang, Duc Anh ^c   Alag, Vibha ^d   Clemens, John D ^a  

^a International Vaccine Institute   (South Korea)

^b Guangxi Center for Disease Control   (China)

^c NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^d Delhi Municipal Corporation   (India)

Author keywords

Asia; China; Immunization; India; Thailand; Typhoid fever; Vaccine; Vi polysaccharide vaccine; Vietnam; Whole cell killed typhoid vaccine

Indexed keywords

TYPHOID VACCINE;

ASIA; CHINA; DRUG FORMULATION; ENDEMIC DISEASE; INCIDENCE; INDIA; MASS IMMUNIZATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; THAILAND; TYPHOID FEVER; VACCINATION; VIET NAM; WORLD HEALTH ORGANIZATION;

ASIA; CHOLERA VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MASS IMMUNIZATION; TRAVEL; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 45849132399     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.5.547     Document Type: Review

References (32)

1. Crump JA, Luby SP, Minta ED. The global burden of typhoid fever. Bull. World Health Organ. 82(5), 346-353 (2004). •• Meta-analysis of population-based studies of typhoid incidence that provides an updated estimate of the global morbidity (22 million cases) and mortality (216,000 deaths) caused by typhoid fever each year.
2. Ochiai RL, Acosta CJ, Danovaro-Holliday MC et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull. World Health Organ. 86(4), 260-268 (2008). •• Multicountry prospective surveillance study of typhoid fever using standardized methods that provides age-specific estimates of annual blood-culture-confirmed typhoid incidence in five study sites in Asia.
3. Steffen R, Rickenbach M, Wilhelm U, Helminger A, Schar M. Health problems after travel to developing countries. J. Infect. Dis. 156, 84-91 (1987).
4. Lawrence J, Jones J. Final Report: Pilot of Enhanced Enteric Fever Surveillance in England, Wales, and Northern Ireland 2008. Health Protection Agency, London, UK (2008).
5. Guzman CA, Borsutzky S, Grio-Wenk M et al. Vaccines against typhoid fever. Vaccine 24, 3804-3811 (2006).
6. Levine MM. Typhoid fever vaccines. In: Vaccines (3rd Edition). Plotkin AS, Orenstein WA (Eds). WB Saunders, PA, USA 781-814 (1999).
7. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull. World Health Organ. 72(6), 957-791 (1994).
8. Klugman KP, Koornhof HJ, Robbins JB, Bouveret LE, Cam NN. Immunogenicity, efficacy and serological correlative of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14, 435-438 (1996).
9. Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans. R. Soc. Trop. Med. Hyg. 98, 423-430 (2004).
10. World Health Organization. WHO report to the Scientific Advisory Group of Experts (SAGE). WHO/GPV/98.06 (1998).
11. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol. Rec. 75, 257-264 (2000).
12. Lin FY, Ho VA, Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344(17), 1263-1269 (2001). •• First Phase III field trial of a Vi conjugate vaccine found that the Vi-rEPA vaccine was 92% efficacious in Vietnamese children 2-5 years of age over 27 months of follow-up and 89% over 46 months of follow-up.
13. Kirkpatrick BD, McKenzie R, O'Neill JP et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24(2), 116-123 (2006).
14. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB. Cellmediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25(8), 1416-1425 (2007).
15. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol. Rec. 83, 49-60 (2008). •• Provides updated information on newgeneration typhoid vaccines and updated recommendations for their use in endemic populations and travelers.
16. Yang HH, Kilgore PE, Yang LH et al. An outbreak of typhoid fever, Xing-An county, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J. Infect. Dis. 183, 1775-1780 (2001). • First study to document the effectiveness of Vi vaccine in providing protection during a currently occurring outbreak of typhoid fever. Receipt of Vi among middle-school students in China during an outbreak was associated with 71% protection compared with 73% among students immunized prior to the outbreak.
17. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of school children with parenteral typhoid vaccine. Rev. Infect. Dis. 9(4), 841-845 (1987). •• Documents the reduction in typhoid fever incidence in several hospitals in Thailand following mass vaccination of school children 7-12 years of age using a killed whole-cell vaccine.
18. Yang HH, Wu CG, Xie GZ et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in southwestern China. Bull. World Health Organ. 79(7), 625-631 (2001).
19. Yang HH. Experience of school-based vaccination in a typhoid fever endemic area using Vi manufactured in China. Presented at: Typhoid Fever, a Neglected Disease: Towards a Vaccine Introduction Policy. Annecy, France, 2-4 April, 2007.
20. Lin M, Gong J, Li C, Liang D, Liao H. [Analysis of diagnosis evidence for notifiable cases with typhoid or paratyphoid fever and strategic research in Guangxi]. J. Guangxi Prev. Med. 10(6), 327-329 (2004).
21. Sinha A, Sazawal S, Kumar R et al. Typhoid fever in children aged less than 5 years. Lancet 354, 734-737 (1999). • Incidence of typhoid fever in children under 5 years of age was double the rate found in any other age group in a slum area of Delhi, India. One of the first studies documenting the high risk of typhoid fever in children under 5 years of age in hyperendemic areas.
22. Clemens JD, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA, 275(5), 390-397 (1996).
23. Acosta CJ, Galindo CM, Ali M et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Trop. Med. Int. Health 10(12), 1219-1228 (2005).
24. Kaljee LM, Pham V, Son ND et al. Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue city, Viet Nam. Trop. Med. Int. Health 12(1), 25-36 (2007).
25. Thiem VD, Danovaro-Holliday MC, Canh DG et al. The feasibility of a school-based Vi polysaccharide vaccine mass immunization campaign in Hue City, Central Vietnam: streamlining a typhoid fever preventive strategy. Southeast Asian J. Trop. Med. Public Health 37(3), 1-8 (2006).
26. Steinberg EB, Bishop R, Haber P et al. Typhoid fever in travelers: who should be targeted for prevention? Clin. Infect. Dis. 39(2), 186-191 (2004).
27. Lin FYC, Ho VA, Bay PV et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am. J. Trop. Med. Hyg. 62(5), 644-648 (2000).
28. Levine MM, Ferreccio C, Black RE, Tacket CO, Germainier R; Chilean Typhoid Committee. Progress in vaccines against typhoid fever. Rev. Infect. Dis. 11(Suppl. 3), S552-S567 (1989).
29. Ochiai RL, Wang XY, von Seidlein L et al. Salmonella Paratyphi A rates, Asia. Emerg. Inf. Dis. 11(11), 1764-1766 (2005).
30. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin. Infect. Dis. 45(Suppl. 1), S24-S28 (2007).
31. GAVI Alliance www.gavialliance.org (Accessed February 2008)
32. National typhoid and paratyphoid fever surveillance www.cdc.gov/ nationalsurveillance/typhoid_surveillance.html (Accessed May 2008)